WuXi Biologics’ Chengdu Microbial Manufacturing Facility Reaches Structural Completion with Key Equipment Installed
WuXi Biologics has reached a major construction milestone in its global manufacturing expansion strategy, announcing the structural completion of its new microbial commercial manufacturing facility in Chengdu, China. The company also confirmed the arrival of key production equipment at the site, signaling steady progress toward its goal of achieving Good Manufacturing Practice (GMP) readiness and initiating commercial production by the end of 2026. This development underscores WuXi Biologics’ continued investment in advanced biologics manufacturing and its ambition to strengthen end-to-end capabilities for global pharmaceutical partners.
Located in the Wenjiang District of Chengdu, the new facility spans approximately 95,000 square meters and has been purpose-built to support large-scale production of microbial-derived biologics. Since breaking ground in June of the previous year, the site has rapidly progressed through construction phases and is now transitioning toward equipment installation, system integration, and operational readiness. Once fully operational, the facility will play a central role in expanding the company’s commercial manufacturing footprint and enhancing its ability to deliver complex biologic therapies to patients worldwide.
The Chengdu site has been designed to support both drug substance (DS) and drug product (DP) manufacturing, making it a fully integrated commercial facility. It is specifically tailored to accommodate a wide range of next-generation therapies that rely on recombinant proteins produced through microbial systems. These include innovative modalities such as antibody-drug conjugates (ADCs), cell therapies, bispecific and multispecific antibodies, and cancer vaccines. Many of these advanced therapies depend on highly specialized protein components, including polypeptides, enzymes, antibody fragments, nanobodies, and cytokines, all of which can be efficiently produced using microbial fermentation technologies.
Microbial fermentation has emerged as a critical platform in modern biologics manufacturing due to its numerous advantages. Compared to traditional mammalian cell culture systems, microbial processes often offer higher yields, faster development timelines, and improved scalability. They also provide consistent production performance and cost efficiencies, making them particularly attractive for emerging therapeutic modalities that require rapid and reliable manufacturing solutions. As the demand for innovative biologics continues to grow, microbial fermentation is increasingly being adopted as a preferred approach across the biopharmaceutical industry.
At the heart of the Chengdu facility is a robust production infrastructure designed to meet commercial-scale demands. The site will be equipped with a 15,000-liter fermenter, enabling the production of up to 110 drug substance batches annually. This capacity can be further expanded over time to reach up to 60,000 liters, providing significant flexibility to accommodate future growth and increasing market demand. Such scalability is essential for supporting therapies that transition from clinical development to widespread commercial use.
In addition to its upstream manufacturing capabilities, the facility will also feature advanced downstream processing and drug product manufacturing technologies. Notably, it will house China’s first dual-chamber lyophilization (freeze-drying) production line, developed in collaboration with VISEN Pharmaceuticals. This specialized system is designed to support the production of complex formulations that require precise control over stability and delivery. The inclusion of a high-capacity vial-filling line, capable of producing more than 10 million vials annually, further enhances the site’s ability to deliver finished drug products at commercial scale.
Beyond physical infrastructure, WuXi Biologics has placed a strong emphasis on digitalization and automation in the design of the Chengdu facility. Integrated digital systems will be deployed across both upstream and downstream operations, enabling real-time monitoring, data collection, and process optimization. These technologies are critical for ensuring compliance with GMP standards, improving operational efficiency, and maintaining high levels of data integrity. By leveraging advanced automation, the company aims to reduce variability, enhance reproducibility, and streamline the overall manufacturing process.
Sustainability has also been a key consideration in the development of the site. The facility incorporates a range of environmental, social, and governance (ESG) principles, including green building practices and energy-efficient design features. For example, the site utilizes a “sponge city” concept to manage water resources effectively, reducing runoff and improving water retention. Additionally, photovoltaic (PV) modules have been integrated into the facility’s infrastructure to generate renewable energy, contributing to lower carbon emissions and improved energy efficiency. These initiatives reflect WuXi Biologics’ broader commitment to sustainable operations and responsible manufacturing practices.
Dr. Chris Chen, Chief Executive Officer of WuXi Biologics, highlighted the strategic importance of the Chengdu site in the company’s global network. He noted that the facility represents a significant step forward in strengthening the company’s commercial-scale microbial capabilities and supporting the growing demand for advanced biologic therapies. According to Chen, the site has been specifically designed to facilitate efficient technology transfer and ensure reliable supply, both of which are critical for meeting the needs of global pharmaceutical innovators.
The Chengdu facility is part of a broader ecosystem that includes research, development, and clinical manufacturing capabilities in Shanghai and Hangzhou. Together, these sites enable WuXi Biologics to offer a fully integrated Contract Research, Development, and Manufacturing Organization (CRDMO) model, providing end-to-end services that span the entire drug development lifecycle. From early-stage strain development to large-scale commercial production, the company is positioned to support clients at every stage of their journey.
A cornerstone of WuXi Biologics’ microbial platform is its proprietary E. coli expression system, known as EffiX™. This technology enables the production of recombinant proteins at titers of up to 15 grams per liter, representing a high level of productivity and efficiency. The platform also supports rapid development timelines, allowing the company to deliver a complete Chemistry, Manufacturing, and Controls (CMC) package—from plasmid DNA construction to Investigational New Drug (IND) filing—in as little as six months. This speed is particularly valuable in today’s fast-paced biopharmaceutical environment, where time-to-market can have a significant impact on patient access and commercial success.
In addition to its high productivity, the microbial platform offers a scalable and flexible production framework. It supports multiple tiers of manufacturing capacity, ranging from 15 liters for early-stage research to 3,000 liters for clinical development and up to 15,000 liters for commercial production. This tiered approach ensures seamless scale-up as drug candidates progress through development stages, reducing the risk of delays and technical challenges.
By the end of 2025, WuXi Biologics’ integrated microbial fermentation platform had already supported the development and manufacturing of 128 molecules, demonstrating its broad applicability and reliability. The addition of the Chengdu facility is expected to further enhance this track record, enabling the company to take on more projects and support a wider range of therapeutic modalities.
As the global biopharmaceutical landscape continues to evolve, the demand for flexible, scalable, and efficient manufacturing solutions is expected to grow. Facilities like the Chengdu microbial site are critical for meeting this demand, particularly as new classes of biologics and advanced therapies move toward commercialization. By investing in state-of-the-art infrastructure, digital technologies, and sustainable practices, WuXi Biologics is positioning itself at the forefront of this transformation.
The structural completion of the Chengdu site marks not just a construction milestone, but a strategic step toward expanding global access to innovative therapies. As the facility moves closer to GMP readiness and eventual production, it is set to play a vital role in accelerating the delivery of life-changing medicines to patients around the world, reinforcing WuXi Biologics’ position as a leading partner in the global biopharmaceutical industry.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore — including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence — WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients’ needs.
By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
Source Link:https://www.wuxibiologics.com/
